These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31705486)

  • 21. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
    Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
    Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
    Paukner S; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Yu K
    Future Microbiol; 2022 Apr; 17(6):397-410. PubMed ID: 35285291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
    Wang H; Charles CV
    Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
    Wicha WW; Strickmann DB; Paukner S
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
    J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).
    Sader HS; Paukner S; Ivezic-Schoenfeld Z; Biedenbach DJ; Schmitz FJ; Jones RN
    J Antimicrob Chemother; 2012 May; 67(5):1170-5. PubMed ID: 22287234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.
    Donald BJ; Surani S; Deol HS; Mbadugha UJ; Udeani G
    Drug Des Devel Ther; 2017; 11():3559-3566. PubMed ID: 29263651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.
    Mendes RE; Paukner S; Doyle TB; Gelone SP; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The wobbly status of ketolides: where do we stand?
    Georgopapadakou NH
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1313-9. PubMed ID: 25154307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Utility of Lefamulin: If Not Now, When?
    Mercuro NJ; Veve MP
    Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hospitalist perspective on treatment of community-acquired bacterial pneumonia.
    Amin AN; Cerceo EA; Deitelzweig SB; Pile JC; Rosenberg DJ; Sherman BM
    Postgrad Med; 2014 Mar; 126(2):18-29. PubMed ID: 24685965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP).
    Cilloniz C; Torres A
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):569-576. PubMed ID: 37728376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
    Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Flamm RK; Rhomberg PR; Sader HS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging antibiotics for community-acquired pneumonia.
    Liapikou A; Cilloniz C; Palomeque A; Torres T
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):221-231. PubMed ID: 31657962
    [No Abstract]   [Full Text] [Related]  

  • 38.
    Jacobsson S; Paukner S; Golparian D; Jensen JS; Unemo M
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.
    Felix TM; Karpa K
    Am Fam Physician; 2020 Sep; 102(6):373-374. PubMed ID: 32931220
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.